Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus
Brief Summary: Arterial stiffness is associated with increased risk for cardiovascular disease. Moreover, the integrity of endothelial glycocalyx plays a vital role in vascular permeability, inflammation and elasticity. Agonists of Glucagon like peptide - 1 receptors (GLP-1R) used in the treatment of type 2 diabetes mellitus (T2DM). This category includes exenatide and liraglutide. These drugs lower glucose levels by inhibiting the secretion of glucagon, promoting the release of insulin in response to hyperglycemia, slowing gastric emptying, and augmenting satiety. Clinical studies have shown that GLP-1R agonists have beneficial effects on cardiovascular function in both diabetic patients and healthy subjects. The purpose of this study is to investigate in patients with T2DM without coronary artery disease (CAD), patients with T2DM and CAD and obese patients with abnormal oral glucose tolerance test (OGTT), changes in arterial stiffness, endothelial glycocalyx thickness and coronary reserve flow (CFR) after treatment with metformin or agonist GLP-1R.


Options:
A: Arm Label: Metformin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Metformin 500 mg (ttd), Drug: Metformin 1000 mg (ttd), Drug: Metformin 1500 mg (ttd), Drug: Metformin 2000 mg (ttd) | Arm Label: Avandamet (Rosiglitazone maleate/metformin hydrochloride); Type: ACTIVE_COMPARATOR; Interventions: Drug: Avandamet 6 mg/1500 mg (ttd), Drug: Avandamet 4 mg/1000 mg (ttd), Drug: Avandamet 2 mg/500 mg (ttd), Drug: Avandamet 8 mg/ 2000 mg (ttd) | Intervention Type: DRUG; Name: Avandamet 6 mg/1500 mg (ttd); Assigned to Arm(s): Avandamet (Rosiglitazone maleate/metformin hydrochloride) | Intervention Type: DRUG; Name: Avandamet 4 mg/1000 mg (ttd); Assigned to Arm(s): Avandamet (Rosiglitazone maleate/metformin hydrochloride) | Intervention Type: DRUG; Name: Avandamet 2 mg/500 mg (ttd); Assigned to Arm(s): Avandamet (Rosiglitazone maleate/metformin hydrochloride) | Intervention Type: DRUG; Name: Avandamet 8 mg/ 2000 mg (ttd); Assigned to Arm(s): Avandamet (Rosiglitazone maleate/metformin hydrochloride) | Intervention Type: DRUG; Name: Metformin 500 mg (ttd); Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Metformin 1000 mg (ttd); Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Metformin 1500 mg (ttd); Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Metformin 2000 mg (ttd); Assigned to Arm(s): Metformin
B: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
C: Arm Label: liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): liraglutide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin
D: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin

Answer: C